The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1728
May 12, 2025
View Complete Issue         Table of Contents 2019 
Concizumab (Alhemo) for Hemophilia A and B with Inhibitors
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Concizumab (Alhemo) for Hemophilia A and B with Inhibitors
May 12, 2025 (Issue: 1728)
Concizumab (Alhemo – Novo Nordisk), a subcutaneously injected tissue factor pathway inhibitor (TFPI) antagonist, has been approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥12...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Concizumab (Alhemo) for Hemophilia A and B with Inhibitors
Article code: 1728c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.